ADVERTISEMENT

Conference Report

ASCO 2022 – The ‘HER2-low revolution’ in breast cancer treatment

Cristina Ferrario — Agenzia Zoe   |   07 June 2022

Takeaway

  • In patients with HER2-low unresectable and/or metastatic breast cancer (mBC), the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy (49% reduction in risk of progression, and 36% reduction in risk of death).
  • No new safety concerns were identified.
  • HER2-low mBC...

          

November Challenge

Ends in 1d 5h
left
right

Topic Challenges

left
right